Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study

BACKGROUND: Apatinib, an oral small-molecule angiogenesis inhibitor, selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), which inhibits vascular endothelial growth factor (VEGF) stimulated endothelial cell migration and proliferation and decreases tumour growth and metastas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Liang, Jianmiao, Gu, Weiguang, Jin, Jun, Zhang, Hua, Chen, Zecheng, Tang, Yicong, Zhang, Shunda, Yang, Shuang, Deng, Yanming, Feng, Weineng
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7745562/
https://ncbi.nlm.nih.gov/pubmed/33403012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920968472
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados